Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations
Clearmind Medicine announced U.S. publication of three patent applications covering proprietary combinations of LSD, ketamine and ibogaine with N-acylethanolamines such as PEA. The applications target indications including depression, PTSD, pain and substance use disorders, and stem from the company's ongoing collaboration with NeuroThera Labs Inc.
Key figures
- Granted patents
- 32
- Published applications
- 3
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.